Literature DB >> 8277194

The effect of deferoxamine on different zygomycetes.

J R Boelaert, M de Locht, Y J Schneider.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8277194     DOI： 10.1093/infdis/169.1.231

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  3 in total

1.  The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.

Authors:  Brad Spellberg; Ashraf S Ibrahim; Peter V Chin-Hong; Dimitrios P Kontoyiannis; Michele I Morris; John R Perfect; David Fredricks; Eric P Brass
Journal:  J Antimicrob Chemother       Date:  2011-09-20       Impact factor: 5.790

2.  Activity of deferasirox in Mucorales: influences of species and exogenous iron.

Authors:  Russell E Lewis; Georgios N Pongas; Nathaniel Albert; Ronen Ben-Ami; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

3.  Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.

Authors:  Brad Spellberg; David Andes; Mario Perez; Anne Anglim; Hector Bonilla; Glenn E Mathisen; Thomas J Walsh; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.